Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Celia Painous^{1

2

3

4}, Andres Perissinotti⁵, Maria J Martí^{1

2

3

4}

Affiliations

¹ Parkinson's Disease & Movement Disorders Unit, Hospital Clínic Barcelona, Barcelona, Spain.
² DIBAPS-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
³ Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
⁴ Universitat de Barcelona, Catalonia, Spain.
⁵ Nuclear Medicine Department, Hospital Clínic Barcelona & Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.

Editorial

Celia Painous et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S351.

doi: 10.21037/atm.2019.09.80.

Celia Painous^{1

2

3

4}, Andres Perissinotti⁵, Maria J Martí^{1

2

3

4}

¹ Parkinson's Disease & Movement Disorders Unit, Hospital Clínic Barcelona, Barcelona, Spain.
² DIBAPS-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
³ Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
⁴ Universitat de Barcelona, Catalonia, Spain.
⁵ Nuclear Medicine Department, Hospital Clínic Barcelona & Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. Wilson H, et al. Lancet Neurol. 2019 Aug;18(8):748-759. doi: 10.1016/S1474-4422(19)30140-1. Epub 2019 Jun 19. Lancet Neurol. 2019. PMID: 31229470

1. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40. 10.1038/42166 - DOI - PubMed
1. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease. Ann Neurol 1990;27:373-85. 10.1002/ana.410270405 - DOI - PubMed
1. Hartmann A. Postmortem studies in Parkinson’s disease. Dialogues Clin Neurosci 2004;6:281-93. - PMC - PubMed
1. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 2008;131:120-31. - PubMed
1. Pagano G, Politis M. Molecular Imaging of the Serotonergic System in Parkinson’s Disease. Int Rev Neurobiol 2018;141:173-210. 10.1016/bs.irn.2018.08.002 - DOI - PubMed